Biogen Inc. shared on Tuesday that its GAAP diluted earnings per share (EPS) for the fourth quarter of fiscal 2022 amounted to $3.79, soaring approximately 52% year over year. In the reported period, on an annual level, total revenue fell 7% to $2.5 billion, while net income attributable to the company jumped 49% to $550 million.
For the whole 2022, the total revenue declined by around 6% when compared to the same timeframe in 2021, landing at $10.2 billion. Net income attributable to Biogen for the twelve months ending December 31, 2022, reached $3.05 billion, surging from $1.5 billion recorded in the same period a year prior. Full-year 2022 diluted EPS skyrocketed 100% on an annual basis, coming in at $20.87.
"Strategically, we are working to put Biogen on a sustainable growth trajectory as we execute on two important near-term opportunities with LEQEMBI in Alzheimer’s disease and zuranolone in depression," CEO Christopher Viehbacher noted.
